Chetasi Talati, MD, discusses the ongoing safety analysis of venetoclax (Venclexta)-based combinations in patients with newly diagnosed acute myeloid leukemia.
Chetasi Talati, MD, hematologic oncology, Moffitt Cancer Center, assistant member, Moffitt Cancer Center in the Department of Malignant Hematology, discusses the ongoing safety analysis of venetoclax (Venclexta)-based combinations in patients with newly diagnosed acute myeloid leukemia.
One factor in the AML Real World Evidence Initiative that is currently under scrupulous investigation is treatment-related mortality, says Talati. Final data have not yet been reported, however, when looking at premlinary results at 3 and 6 months, investigators saw Kaplan Meier survival rates of 100% versus 79% for venetoclax treatment combined with hypomethylating agents (HMAs) and 75% versus 48% in the control cohort, which was comprised of high-intensity treatments and other cytarabine-based regimens.
This preliminary data truly shed light on how well venetoclax plus HMAs is tolerated in this patient population; however, longer-term follow-up is needed, and investigators are particularly interested in seeing the 30-day and 60-day mortality rates with the venetoclax-based combinations, says Talati.
Additionally, investigators continue to study the adverse events associated with the agent, specifically cytopenia and invasive fungal infections. To this end, data regarding the number of hospitalizations that could potentially result in treatment interruptions continue to be collected, concludes Talati.